Researchers at the Institute of Cancer Research (ICR) in London have designed a prototype test that they think could be used to predict which combinations are likely to work in cancer patie
Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks.
Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returnin
Bristol-Myers Squibb's Opdivo has been playing second fiddle to Merck & Co's Keytruda in the non-small cell lung cancer (NSCLC) market for years, but now it has a chance to take the lim
FDA advisors have voted against approval of Eli Lilly and Innovent Biologics' cancer immunotherapy sintilimab, undermining hopes of a new, lower-priced option in the PD-1/PD-L1 inhibitor cl
The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ahead of an advisory committee meeting due to take place on Thursday.